Physician profile
Amber Ojeda
NPI 1881199255
$2,309.43
in general payments reported to CMS, 2019-2025
16 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,194 · 2023: $834 · 2024: $102 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072 · Education: $44.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.63 |
| Education | $44.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $408.65 | 2022-2023 | Dupixent |
| Optinose US, INC. | $394.00 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $263.18 | 2022-2025 | Fasenra |
| Csl Behring | $242.33 | 2022-2024 | Haegarda, Hizentra |
| Glaxosmithkline, LLC. | $224.15 | 2022-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $208.29 | 2022-2023 | |
| Octapharma USA, INC. | $138.06 | 2022-2024 | Cutaquig |
| Alk-Abello, INC | $112.87 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Grifols USA, LLC | $95.72 | 2022-2025 | Xembify, Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $62.59 | 2022-2023 | Cuvitru |
| Covis Pharma Gmbh | $47.79 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $30.09 | 2025 | Neffy |
| Genentech USA, INC. | $23.86 | 2022 | |
| Kaleo, INC. | $20.83 | 2022 | |
| Aimmune Therapeutics, INC. | $19.01 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Ojeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.